DHA supplementation decreases serum C-reactive protein and other markers of inflammation in hypertriglyceridemic men

Journal of Nutrition

Volumn 139, Issue 3, 2009, Pages 495-501

  Kelley, Darshan S ^a,b   Siegel, David ^c,d   Fedor, Dawn M ^a,b   Adkins, Yuriko ^a,b   Mackey, Bruce E ^e  

^a AGRICULTURAL RESEARCH SERVICE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^e WESTERN REGIONAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; DOCOSAHEXAENOIC ACID; GELATINASE A; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 6; LIPID; OLIVE OIL; PLACEBO; SERUM AMYLOID A; VERY LOW DENSITY LIPOPROTEIN; LIPOPROTEIN;

ADULT; AGED; BLOOD SAMPLING; BODY WEIGHT; CIRCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DIET SUPPLEMENTATION; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ERYTHROCYTE; HUMAN; HYPERTRIGLYCERIDEMIA; INFLAMMATION; LIPID BLOOD LEVEL; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; MALE; NEUTROPHIL COUNT; PARALLEL DESIGN; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; ARTICLE; BLOOD; LEUKOCYTE; METABOLISM; MIDDLE AGED;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; HUMANS; HYPERTRIGLYCERIDEMIA; INFLAMMATION; LEUKOCYTES; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED;

EID: 62749187788     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.108.100354     Document Type: Conference Paper

References (46)

1. AHA. Heart disease and stroke statistics: 2007 update. AHA. Sept 25, 2007 [cited 2008 2 Sept]. Available from: www.americanheart.org.
2. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363-9.
3. Morrow DA. Screening for cardiovascular risk with C-reactive protein. 2007 [cited 2008 2 Sept]. Available from: www.utdonline.com.
4. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351: 2599-610.
5. Ridker PM, Buring JE, Shih J, Mafias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-3.
6. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular dis ease in women. N Engl J Med. 2000;342:836-43.
7. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347: 1557-65.
8. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-97.
9. Burdge GC, Calder PC. Plasma cytokine response during the postpran dial period: a potential causal process in vascular disease? Br J Nutr. 2005;93:3-9.
10. Matsusaka H, Ikeuchi M, Matsushima S, Ide T, Kubota T, Feldman AM, Takeshita A, Sunagawa K, Tsutsui H. Selective disruption of MMP-2 gene exacerbates myocardial inflammation and dysfunction in mice with cytokine-induced cardiomyopathy. Am J Physiol Heart Circ Physiol. 2005;289:H1858-64.
11. Corry DB, Rishi K, Kanellis J, Kiss A, Song LZ, Xu J, Feng L, Werb Z, Kheradmand F. Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP2-deficiency. Nat Immunol. 2002;3:347-53.
12. Itoh T, Matsuda H, Tanioka M, Kuwabara K, Itohara S, Suzuki R. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J Immunol. 2002;169:2643-7.
13. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myo cardial ischemia and reperfusion injury. Circulation. 2002;106:1543-9.
14. Kelley DS, Taylor PC, Nelson GJ, Mackey BE. Dietary docosahexaenoic acid and immunocompetence in young healthy men. Lipids. 1998;33: 559-66.
15. Kelley DS, Taylor PC, Nelson GJ, Schmidt PC, Mackey BE, Kyle D. Effects of dietary arachidonic acid on human immune response. Lipids. 1997;32:449-56.
16. Fernandez-Real JM, Broch M, Vendrell J, Ricart W Insulin resistance, inflammation, and serum fatty acid composition. Diabetes Care. 2003; 26:1362-8.
17. Fredrikson GN, Hedblad B, Nilsson JA, Alm R, Berglund G, Nilsson J. Association between diet, lifestyle, metabolic cardiovascular risk fac tors, and plasma C-reactive protein levels. Metabolism. 2004;53: 1436-42.
18. Lopez-Garcia E, Schulze MB, Manson JE, Meigs JB, Albert CM, Rifai N, Willett WC, Hu FB. Consumption of (n-3) fatty acids is related to plasma biomarkers of inflammation and endothelial activation in women. J Nutr. 2004;134:1806-11.
19. Niu K, Hozawa A, Kuriyama S, Ohmori-Matsuda K, Shimazu T, Nakaya N, Fujita K, Tsuji I, Nagatomi R. Dietary long-chain n-3 fatty acids of marine origin and serum C-reactive protein concentrations are associated in a population with a diet rich in marine products. Am J Clin Nutr. 2006;84:223-9.
20. Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Willett WC, Rimm EB. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation. 2003; 108:155-60.
21. Zampelas A, Panagiotakos DB, Pitsavos C, Das UN, Chrysohoou C, Skoumas Y, Stefanadis C. Fish consumption among healthy adults is associated with decreased levels of inflammatory markers related to cardiovascular disease: the ATTICA study. J Am Coll Cardiol. 2005; 46:120-4.
22. Madsen T, Skou HA, Hansen VE, Fog L, Christensen JH, Toft E, Schmidt EB. C-reactive protein, dietary n-3 fatty acids, and the extent of coronary artery disease. Am J Cardiol. 2001;88:1139-42.
23. Mori TA, Woodman RJ, Burke V, Puddey IB, Croft KD, Beilin LJ. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic sub jects. Free Radic Biol Med. 2003;35:772-81.
24. Chan DC, Watts GF, Mori TA, Barrett PH, Redgrave TG, Beilin LJ. Randomized controlled trial of the effect of n-3 fatty acid supplemen tation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity. Am J Clin Nutr. 2003;77:300-7.
25. Madsen T, Christensen JH, Blom M, Schmidt EB. The effect of dietary n-3 fatty acids on serum concentrations of C-reactive protein: a doseresponse study. Br J Nutr. 2003;89:517-22.
26. Geelen A, Brouwer IA, Schouten EG, Kluft C, Katan MB, Zock PL. Intake of n-3 fatty acids from fish does not lower serum concentrations of C-reactive protein in healthy subjects. Eur J Clin Nutr. 2004;58: 1440-2.
27. Madsen T, Christensen JH, Schmidt EB. C-reactive protein and n-3 fatty acids in patients with a previous myocardial infarction: a placebocontrolled randomized study. Eur J Nutr. 2007;46:428-30.
28. Sanders TA, Gleason K, Griffin B, Miller GJ. Influence of an algal triacylglycerol containing docosahexaenoic acid (22: 6n-3) and docosapentaenoic acid (22: 5n-6) on cardiovascular risk factors in healthy men and women. Br J Nutr. 2006;95:525-31.
29. Murphy KJ, Meyer BJ, Mori TA, Burke V, Mansour J, Patch CS, Tapsell LC, Noakes M, Clifton PA, et al. Impact of foods enriched with n-3 long-chain polyunsaturated fatty acids on erythrocyte n-3 levels and cardiovascular risk factors. Br J Nutr. 2007;97:749-57.
30. Ciubotaru I, Lee YS, Wander RC. Dietary fish oil decreases C-reactive protein, interleukin-6, and triacylglycerol to HDL-cholesterol ratio in postmenopausal women on HRT. J Nutr Biochem. 2003;14:513-21.
31. Sundrarjun T, Komindr S, Archararit N, Dahlan W, Puchaiwatananon O, Angthararak S, Udomsuppayakul U, Chuncharunee S. Effects of n-3 fatty acids on serum interleukin-6, tumour necrosis factor-alpha and soluble tumour necrosis factor receptor p55 in active rheumatoid ar thritis. J Int Med Res. 2004;32:443-54.
32. Tsitouras PD, Gucciardo F, Salbe AD, Heward C, Harman SM. High omega-3 fat intake improves insulin sensitivity and reduces CRP and IL6, but does not affect other endocrine axes in healthy older adults. Horm Metab Res. 2008;40:199-205.
33. Calder PC. N-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids. 2003;38:343-52.
34. Kelley DS, Siegel D, Vemuri M, Chung GH, Mackey BE. Docosahex aenoic acid supplementation decreases remnant-like particle-cholesterol and increases the (n-3) index in hypertriglyceridemic men. J Nutr. 2008; 138:30-5.
35. Kelley DS, Siegel D, Vemuri M, Mackey BE. Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men. Am J Clin Nutr. 2007;86:324-33.
36. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106: 2747-57.
37. ClinicalTrials.gov [Internet]. USDA; Western Human Nutrition Re search Center. Bethesda (MD): National Library of Medicine (US). 2003-2005. Effect of docosahexenoic acid (22:6n-3, DHA) supplemen tation on risk factors for cardiovascular disease in hyperlipidemic men [cited 2008 Dec 2]. Available from http://clinicaltrials.gov/show/NCT00728338-NLM Identifier: NCT00728338.
38. Kelley DS, Taylor PC, Nelson GJ, Schmidt PC, Ferretti A, Erickson KL, Yu R, Chandra RK, Mackey BE. Docosahexaenoic acid ingestion inhibits natural killer cell activity and production of inflammatory mediators in young healthy men. Lipids. 1999;34:317-24.
39. Mifflin MD, St Jeor ST, Hill LA, Scott BJ, Daugherty SA, Koh YO. A new predictive equation for resting energy expenditure in healthy individuals. Am J Clin Nutr. 1990;51:241-7.
40. SAS Institute. SAS online Doc 9.1.3 ed. Cary (NC): SAS Institute, Inc.; 2004.
41. Littell RC, Milliken GA, Stroup WW, Wolfinger RD, Schabenberger O. SAS system for mixed models. 2nd ed. Cary (NC): SAS Institute, Inc.; 2006.
42. Carlyle WC, Jacobson AW, Judd DL, Tian B, Chu C, Hauer KM, Hartman MM, McDonald KM. Delayed reperfusion alters matrix metalloproteinase activity and fibronectin mRNA expression in the infarct zone of the ligated rat heart. J Mol Cell Cardiol. 1997;29:2451-63.
43. Hayashidani S, Tsutsui H, Ikeuchi M, Shiomi T, Matsusaka H, Kubota T, Imanaka-Yoshida K, Itoh T, Takeshita A. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol. 2003;285: H1229-35.
44. Hansen RA, Harris MA, Pluhar GE, Motta T, Brevard S, Ogilvie GK, Fettman MJ, Allen KG. Fish oil decreases matrix metalloproteinases in knee synovia of dogs with inflammatory joint disease. J Nutr Biochem. 2008;19:101-8.
45. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evalu ation (PRINCE): a randomized trial and cohort study. JAMA. 2001; 286:64-70.
46. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001;103:1933-5.